Lavipharm S.A (AT:LAVI) — Market Cap & Net Worth
Market Cap & Net Worth: Lavipharm S.A (LAVI)
Lavipharm S.A (AT:LAVI) has a market capitalization of $287.04 Million (€245.52 Million) as of September 16, 2026. Listed on the AT stock exchange, this Greece-based company holds position #15097 globally and #40 in its home market, demonstrating a -1.37% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lavipharm S.A's stock price €1.58 by its total outstanding shares 169043561 (169.04 Million). Also see Lavipharm S.A balance sheet assets for a full breakdown of the balance sheet.
Lavipharm S.A Market Cap History: 2015 to 2026
Lavipharm S.A's market capitalization history from 2015 to 2026. Data shows growth from $77.25 Million to $312.25 Million (10.58% CAGR). Also see Lavipharm S.A cash conversion from operations for how efficiently the company converts equity into cash flow.
Lavipharm S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lavipharm S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Lavipharm S.A for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.97x
Lavipharm S.A's market cap is 2.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.49x
Lavipharm S.A's market cap is 17.49 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $77.25 Million | $26.37 Million | -$7.07 Million | 2.93x | N/A |
| 2016 | $47.47 Million | $31.14 Million | $3.66 Million | 1.52x | 12.97x |
| 2017 | $90.51 Million | $31.81 Million | $12.93 Million | 2.85x | 7.00x |
| 2018 | $77.25 Million | $34.06 Million | $1.25 Million | 2.27x | 61.85x |
| 2019 | $121.40 Million | $33.59 Million | $5.33 Million | 3.61x | 22.79x |
| 2020 | $259.39 Million | $37.64 Million | $2.17 Million | 6.89x | 119.81x |
| 2021 | $320.08 Million | $39.72 Million | $1.72 Million | 8.06x | 185.77x |
| 2022 | $75.89 Million | $46.01 Million | $834.00K | 1.65x | 90.99x |
| 2023 | $157.31 Million | $47.84 Million | $1.87 Million | 3.29x | 84.08x |
| 2024 | $157.12 Million | $52.95 Million | $8.98 Million | 2.97x | 17.49x |
Competitor Companies of LAVI by Market Capitalization
Companies near Lavipharm S.A in the global market cap rankings as of September 16, 2026. Review LAVI goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Lavipharm S.A by market ranking:
- Medicon Hellas S.A. (AT:MEDIC): Ranked #26644 globally with a market cap of $12.15 Million USD ( €10.40 Million EUR).
- Kendrion NV (AS:KENDR): Ranked #15088 globally with a market cap of $287.37 Million USD ( €245.81 Million EUR).
- YG-1 Co. Ltd (KQ:019210): Ranked #15089 globally with a market cap of $287.36 Million USD ( ₩424.04 Billion KRW).
- Nongshim Holdi (KO:072710): Ranked #15098 globally with a market cap of $286.95 Million USD ( ₩423.43 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #26644 | Medicon Hellas S.A. | AT:MEDIC | $12.15 Million | €2.69 |
| #15088 | Kendrion NV | AS:KENDR | $287.37 Million | €18.98 |
| #15089 | YG-1 Co. Ltd | KQ:019210 | $287.36 Million | ₩12630.00 |
| #15098 | Nongshim Holdi | KO:072710 | $286.95 Million | ₩91300.00 |
Lavipharm S.A Historical Marketcap From 2015 to 2026
Between 2015 and today, Lavipharm S.A's market cap moved from $77.25 Million to $ 312.25 Million, with a yearly change of 10.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €312.25 Million | +62.89% |
| 2025 | €191.70 Million | +22.01% |
| 2024 | €157.12 Million | -0.13% |
| 2023 | €157.31 Million | +107.29% |
| 2022 | €75.89 Million | -76.29% |
| 2021 | €320.08 Million | +23.40% |
| 2020 | €259.39 Million | +113.66% |
| 2019 | €121.40 Million | +57.15% |
| 2018 | €77.25 Million | -14.65% |
| 2017 | €90.51 Million | +90.67% |
| 2016 | €47.47 Million | -38.55% |
| 2015 | €77.25 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Lavipharm S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $287.04 Million USD |
| MoneyControl | $287.04 Million USD |
| MarketWatch | $287.04 Million USD |
| marketcap.company | $287.04 Million USD |
| Reuters | $287.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lavipharm S.A
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs,… Read more